Skip to content
Close (esc)

BECOME A FRIEND OF EFILA!

Join our mailing list and get health information and updates on promotions! 15% off your first purchase!

The Story of EFILA

At EFILA™, we believe true wellness begins at the cellular level. Our 100% natural formula, crafted from bioengineered mushroom mycelium, delivers targeted cellular nutrition to:
✓ Protect pancreatic beta cells from apoptosis
Promote healthy insulin function through natural metabolic support
✓ Support your body’s innate ability to manage glucose

Why EFILA™?
🌿 IP Fortress: The World’s First Two Patented Strains 6 patents (KR/CN/PCT)
🛡️ HSA-Certified Safety
📊 70+ Clinical Cases, Improvement in Insulin Resistance | Kyung Hee University validated

Cellular Nutrition: The Foundation of Metabolic Health

From Cell to System: EFILA’s Triple-Action Precision Powers Beta Cell Health and Insulin Balance

Our Journey: From Forest Discovery to Global Innovation

Rooted in Nature, Validated by Science


2005: A Breakthrough in the Korean Forests

  • Foundational Discovery: Dr. Kim Byoungcheon, a visionary scientist with a PhD in Biomedical Sciences (Western California Medical University), discovers Ceriporia lacerata — a rare medicinal mushroom growing on Korean pine trees.
  • Initial Findings: In Vitro and In Vivo studies revealed its extraordinary potential to lower blood glucose level and protect pancreatic beta cells from apoptosis, etc., sparking a 20-year R&D mission

2005–2015: Decoding Nature’s Blueprint

  • Strain Optimization: Patented fermentation technology refines Ceriporia lacerata into a standardized bioactive extract.
  • Preclinical Validation:
     4 Toxicity Tests — Confirmed safety across organ systems.
     Animal Studies — Demonstrated 30% blood sugar reduction in diabetic models (Int. J. Mol. Med, 2013).
  • Global Recognition: Dr. Kim awarded the Grand Prize at EURO INVENT 2015 for advancing natural diabetes solutions.

2016–2021: From Lab to Life

  • Human Trials Begin: Phase I trials at Kyung Hee University validate:
     7.7 mg/dL fasting glucose reduction (BMC Complementary Medicine, 2023).
     Zero adverse effects across 70+ participants.
  • Patented Evolution:
     Ceriporia lacerata K1 — 3 patents in KR.
     Irpex lacteus I.K —1 patent in KR; 1 patent in CN, 1 patent in PCT.

2022–Present: Rewriting Diabetes Care

  • EFILA™ : Obtain global patents for  EFILA — a compound derived from dual-strain fermentation, targeting:
    ✓ Beta cell regeneration (Journal of Diabetes Research, 2022).
    ✓ Systemic insulin sensitivity (Food Sci Biotechnol, 2021).
  • Industry Chain Mastery: Full-cycle control from strain cultivation (KACC-certified) to HSA-approved formulations.
  • Global Vision: Partnering with health supplement/pharmaceutical companies to bring this unique dietary supplement to help 500M+ at-risk patients..

Why Trust EFILA?

  • 20 years’ basic and clinical research, 9 SCI papers: Rigorously validated by institutions like Kyung Hee University,
  • Ethics in Action:
    ✓ 100% natural, traceable ingredients.

 

Back to top